Biotech grants in Denmark
Explore Biotech grants for companies in Denmark. This list brings together funding for drug discovery, diagnostics, cell and gene therapy, biomanufacturing and life-science research from Danish innovation agencies, research funders and foundations, EU and international programs open to applicants in Denmark, and competitions any company can enter, with the deadline, award size and eligibility on every listing. Grants aimed at Biotech in Denmark come first.
Showing 193-216 of 649 grants
Translating Disruptive New Approach Methodologies (NAMs) into Practice
🇪🇺European Commission · European Union
Pays biomedical New Approach Methodology developers a fixed EUR 300,000 lump-sum grant to validate animal-free testing methods and prepare them for regulatory use.
Understanding how infections foster and induce non-communicable diseases
🇪🇺IHI JU · European Union
Funds one project mining research cohorts and biobanks to find causal links between infections and non-communicable diseases, aimed at new vaccines, diagnostics and early treatments.
Understanding the effects of environmental exposure on the risk of paediatric, adolescent and young adult cancers
🇪🇺European Commission · European Union
Funds research into how environmental exposures interact with genetic and lifestyle factors to cause cancer in children, adolescents and young adults.
Unleashing the potential and advancing the impact of the digitalization/Artificial Intelligence of the climate-neutral bio-based value chains
🇪🇺European Commission · European Union
Funds AI and digital-twin tools that speed up bio-based manufacturing — from biorefinery process control to predicting biosynthesis pathways.
Urban-industrial symbiosis for bio-waste valorisation
🇪🇺CBE JU · European Union
Funds a full-scale flagship biorefinery that turns separately-collected urban bio-waste into higher-value bio-based products instead of compost or biomethane.
Vaccine Development for Epidemic-Potential Viruses
🇪🇺European Commission · European Union
Funds the advancement of existing vaccine candidates against one named epidemic-prone virus, from lab testing through to a first human safety trial.
Valorisation of untapped forest biomass
🇪🇺CBE JU · European Union
Funds research into new tools and conversion routes that turn low-value forest residues into bio-based chemicals, materials or products beyond bioenergy.
EUopSTART — cut-off
🇩🇰UFM · Denmark
Funds Danish companies preparing Horizon Europe and EDF proposals by supporting proposal development.
GREGoRi Innovation Projects
NIH · United States
Funds a genuinely new experimental or computational approach to finding the cause of a rare genetic disorder, where the current state of the art falls short.
FY26 Reconstructive Transplant Research Program Concept Award
CDMRP · United States
Funds small, high-risk exploratory research into reconstructive transplantation and vascularized composite allotransplantation for wounded Service Members and Veterans.
Xcelerate Champion of Innovation
WHX Tech · United Arab Emirates
Pays an equity-free cash prize to the top healthcare startup pitching live at WHX Tech's Xcelerate competition in Dubai.
Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01)
NIH · United States
Funds theory and method development on how genetic and non-genetic factors together produce variation in complex traits, tested against large existing datasets.
Strategic Research Agreement — Round 1
Breakthrough T1D · United States
Funds investigator-led type 1 diabetes research partnerships across preclinical discovery, treatment, and translational priorities.
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01)
NIH · United States
Funds new analysis of clinical, genomic, environmental and registry data that already exists, to sharpen who is at risk of cancer and what happens to them.
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research
NIH · United States
Funds the development and hard technical validation that turns a working cancer research technology into one other laboratories will actually adopt.
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research
NIH · United States
Funds proof-of-concept work on a genuinely new tool, assay, platform or instrument for characterising cancer cells or handling biospecimens.
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21)
NIH · United States
Funds the same reanalysis of already-collected cancer data on a smaller, exploratory footing, for teams that do not need a full research project award.
Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant
NIH · United States
Funds exploratory studies of the ethical, legal and social consequences of human genetics, especially where a technology or a use of genomic data is new.
Ethical, Legal and Social Implications (ELSI) Research
NIH · United States
Funds a full research project on the ethics, law and social effects of human genetics — and refuses to review an application with no diverse-perspectives plan.
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)
NIH · United States
Funds one bundled run from first-in-human through phase 2a for a dementia drug that works on something other than amyloid or tau.
Lupus Insight Prize
LRA · United States
Provides prize recognizing a specific significant recent lupus research discovery through the Lupus Insight Prize.
Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21)
NIH · United States
Funds the exploratory version of the same theory-and-methods work on complex trait variation, for ideas that need testing before a larger project is justified.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01)
NIH · United States
Funds work on how GLP-1 and related drugs change cancer risk — raising it for some cancers, lowering it for others.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21)
NIH · United States
Funds smaller, higher-risk work on how GLP-1 and related drugs change cancer risk. No clinical trial in this version.